Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
78 hedge funds and large institutions have $306M invested in Avadel Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 31 increasing their positions, 20 reducing their positions, and 5 closing their positions.
100% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 5
55% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 20
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
13% more capital invested
Capital invested by funds: $270M → $306M (+$35.4M)
5% more funds holding
Funds holding: 74 → 78 (+4)
0.39% less ownership
Funds ownership: 67.42% → 67.03% (-0.39%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$21.9M |
| 2 |
Renaissance Technologies
New York
|
+$6.89M |
| 3 |
Millennium Management
New York
|
+$6.21M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$3.6M |
| 5 |
Morgan Stanley
New York
|
+$2.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
-$17.2M |
| 2 |
DM
Deerfield Management
New York
|
-$4.19M |
| 3 |
JGC
J. Goldman & Co
New York
|
-$3.32M |
| 4 |
BC
Broadfin Capital
New York
|
-$2.62M |
| 5 |
BCM
Brown Capital Management
Baltimore,
Maryland
|
-$929K |
AVDL Hedge Fund Activity: Q2 2017 in Review
78 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q2 2017, worth a combined $306M — up 13% from $270M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new AVDL positions and 5 closed out — a net gain of 5 holders — while 31 added to existing stakes and 20 trimmed.
The largest buyer was Janus Henderson Group, opening a new position worth an estimated $21.9M. The largest seller was Bank of New York Mellon, exiting entirely with an estimated $17.2M sold.
- 78 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q2 2017, up from 74 in Q1 2017.
- Funds reported $306M of Avadel Pharmaceuticals stock for Q2 2017, up 13% quarter-over-quarter.
- 10 funds opened new Avadel Pharmaceuticals positions in Q2 2017 and 5 closed out, a net change of +5 holders.
- The largest Avadel Pharmaceuticals buyer in Q2 2017 was Janus Henderson Group, an estimated $21.9M added.
- The largest Avadel Pharmaceuticals seller in Q2 2017 was Bank of New York Mellon, an estimated $17.2M sold.
Based on aggregated 13F filings for Q2 2017.